Contents
Clinical research in New Hampshire is a way to bring novel therapies to patients who don’t respond to regular treatment. All clinical trials must meet strict criteria and are subject to supervised federal oversight.
You too can be a part of something new. We are here to help you find a clinical trial that can suit your needs.
Clinical Trials For Disease Areas in New Hampshire
Clinical research trials in New Hampshire have a variety of research strengths that span across different disease areas. From heart problems to cancer, neurologic complications, immunology, dermatology, and reproductive health.
Over the past two decades, state experts have done thousands of clinical trials in a multitude of indications. In the last 9 years, Southern New Hampshire Diabetes and Endocrinology has been conducting research on diabetes.
Many clinical trials have been completed in type 1 and type 2 diabetes. Right now, they are involved in studies sponsored by pharmaceutical companies. These studies are designed to test new products for type 1 and type 2 diabetes.
Want to be a part of a clinical trial? Browse the list below and sign up for a trial today.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire +12 locations
New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire
Parkland Medical Center, Derry, New Hampshire
Wentworth-Douglass Hospital, Dover, New Hampshire
Exeter Hospital, Exeter, New Hampshire
LRGHealthcare-Lakes Region General Hospital, Laconia, New Hampshire
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
The Dana-Farber Cancer Institute at Londonderry, Londonderry, New Hampshire
Norris Cotton Cancer Center-Manchester, Manchester, New Hampshire
Elliot Hospital, Manchester, New Hampshire
Solinsky Center for Cancer Care, Manchester, New Hampshire
Saint Joseph Hospital, Nashua, New Hampshire
Norris Cotton Cancer Center-Nashua, Nashua, New Hampshire
Portsmouth Regional Hospital, Portsmouth, New Hampshire
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
Recruiting
Advanced airway interventions are common high risk, high stakes events for children in intensive care units (ICU) and emergency departments (ED), with risk for life and health threatening consequences.
Advanced airway interventions are common high risk, high stakes events for children in intensive care units (ICU) and emergency departments (ED), with risk for life and health threatening consequences. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
01/21/2025
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Quality of Pediatric Resuscitation in a Multicenter Collaborative
Recruiting
This is a prospective, observational, multi-center cohort study of pediatric cardiac arrests.
The purpose of the study is to determine the association between chest compression mechanics (rate, depth, flow fraction, compression release) and patient outcomes. In addition, the investigators will determine the association of post cardiac arrest care with patient outcomes.
This is a prospective, observational, multi-center cohort study of pediatric cardiac arrests.
The purpose of the study is to determine the association between chest compression mechanics (rate, depth, flow fraction, compression release) and patient outcomes. In addition, the investigators will determine the association of post cardiac arrest care with patient outcomes. Read Less
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
04/12/2024
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Cardiac Arrest, Cardiopulmonary Arrest
PARTNER 3 Trial - Aortic Valve-in-Valve
Recruiting
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve.
This study will assess the safety and effectiveness of the SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve (THV) in patients with a failing aortic bioprosthetic valve. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
05/08/2024
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Recruiting
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate t... Read More
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification.
This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort.
Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Catholic Medical Center, Manchester, New Hampshire
Catholic Medical Center, Manchester, New Hampshire
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
Recruiting
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the in... Read More
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Dartmouth-Hitchcock Medical Center /ID# 169097, Lebanon, New Hampshire
Dartmouth-Hitchcock Medical Center /ID# 169097, Lebanon, New Hampshire
Conditions: Hematologic Malignancies
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Recruiting
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. Read Less
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/14/2024
Locations: New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire +4 locations
New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire
Wentworth-Douglass Hospital, Dover, New Hampshire
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Elliot Hospital, Manchester, New Hampshire
Solinsky Center for Cancer Care, Manchester, New Hampshire
Conditions: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire +2 locations
New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire
Elliot Hospital, Manchester, New Hampshire
Solinsky Center for Cancer Care, Manchester, New Hampshire
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire +4 locations
New Hampshire Oncology Hematology PA-Concord, Concord, New Hampshire
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Dartmouth Cancer Center - Manchester, Manchester, New Hampshire
Solinsky Center for Cancer Care, Manchester, New Hampshire
Dartmouth Cancer Center - Nashua, Nashua, New Hampshire
Conditions: Previously Treated Non-Small Cell Lung Cancer
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.
After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.
After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Dartmouth Hitchcock Med Ctr/Dartmouth Cancer Ctr, Lebanon, New Hampshire
Dartmouth Hitchcock Med Ctr/Dartmouth Cancer Ctr, Lebanon, New Hampshire
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Paid Clinical Trials in New Hampshire
Paid clinical trials can offer a small boost to your finances. You can get paid, get access to free medical treatment, or receive other forms of compensation.
For example, you can receive financial benefits by taking part in a study that is meant to test a new therapy or medication. In cases such as these, you might receive a placebo. NH paid clinical trials serve the purpose of providing experts with more data.
Clinical Trials For Health Volunteers in New Hampshire
Some research teams in New Hampshire recruit healthy volunteers to take part in clinical trials. These studies can offer preliminary information about a newly designed drug, vaccine, or therapy. Health volunteers are usually needed in the early stages of a trial.
Become a vital part of medical discovery. Check the list below for clinical trials near you.
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
Recruiting
Background:
Diet is one of the most modifiable behaviors affecting health. But diet assessment measures that are based on self-report can be inaccurate. Researchers want better ways to address the role of diet in chronic disease. They want to see if stable isotopes can be used to better assess what people eat.
Objective:
To see if stable isotopes can help scientists identify things people eat.
Eligibility:
Healthy adults ages 18 to 65
Design:
Participants will be screened with a medical h... Read More
Background:
Diet is one of the most modifiable behaviors affecting health. But diet assessment measures that are based on self-report can be inaccurate. Researchers want better ways to address the role of diet in chronic disease. They want to see if stable isotopes can be used to better assess what people eat.
Objective:
To see if stable isotopes can help scientists identify things people eat.
Eligibility:
Healthy adults ages 18 to 65
Design:
Participants will be screened with a medical history and physical exam. They will have blood and urine tests. These tests will be repeated during the study.
Participants will stay in the inpatient unit of the NIH in Phoenix, Arizona, for 13 weeks.
For 7 days, participants will eat a diet prepared by the NIH kitchen. They will get balanced meals that are 50% carbohydrates, 20% protein, and 30% fat. Then participants will be randomly placed on one of 3 diets containing different percentages of carbohydrates from soda.
Participants height and weight will be measured. The amount of fat and muscle in their body will be measured by body scans that are similar to x-rays.
Participants will have oral glucose tolerance tests. They will consume a sugar drink and then give blood samples over 3 hours.
Participants will give hair and stool samples.
Participants will complete a diet questionnaire. It assesses their food intake over 24 hours.
Participants will complete behavioral questionnaires and computer performance tests.
Participants will have fat biopsies taken from their stomach and thigh.
Participants will have three 24-hour stays in a metabolic chamber. It is used to measure metabolism. Read Less
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/31/2025
Locations: NIDDK, Phoenix, Phoenix, Arizona
NIDDK, Phoenix, Phoenix, Arizona
Conditions: Diet Therapy, Healthy Volunteers
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
Recruiting
The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.
The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Healthy
The Effects of Increasing Caloric Intake on Diet-Induced Thermogenesis and 24h Energy Expenditure
Recruiting
Background:
Diet-induced thermogenesis (DIT) is the amount of energy one s body uses to eat food, absorb the nutrients from the food, and process those nutrients. Researchers would like to understand more about how changing the balances of protein, fat, carbohydrates, and total calories in the diet can affect DIT.
Objective:
To learn how different diets can change a person s DIT.
Eligibility:
Healthy people aged 18 to 60 years who have not intentionally lost weight in the past 6 months.
De... Read More
Background:
Diet-induced thermogenesis (DIT) is the amount of energy one s body uses to eat food, absorb the nutrients from the food, and process those nutrients. Researchers would like to understand more about how changing the balances of protein, fat, carbohydrates, and total calories in the diet can affect DIT.
Objective:
To learn how different diets can change a person s DIT.
Eligibility:
Healthy people aged 18 to 60 years who have not intentionally lost weight in the past 6 months.
Design:
Participants will stay in a clinic for about 35 days. They will eat only the food provided. They will receive 8 different diets during the study, including 7 test diets.
Participants will undergo multiple tests.
They will be screened with blood and urine tests and a test of their heart function.
During the first few days:
Their waist, thigh, and neck circumference will be measured.
They will have a DXA scan: They will lie on a padded table for about 20 minutes while an instrument measures the amount of fat in their body.
They will be tested for diabetes.
They will answer questionnaires about topics including eating behavior, hunger, and stress.
Throughout the study:
Their weight will be measured daily.
Blood tests will be repeated.
They will stay in a metabolic chamber a total of 9 times. They will remain in a closed room for 24 hours while researchers monitor the room temperature and levels of oxygen and carbon dioxide. Participants will collect all their urine for each 24-hour period.
... Read Less
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
07/31/2025
Locations: NIDDK, Phoenix, Phoenix, Arizona
NIDDK, Phoenix, Phoenix, Arizona
Conditions: Obesity, Normal Physiology, Healthy Volunteers
A Study of Neurodegeneration and Neuronal Fluctuations in Lewy Body Disease and Alzheimer's Disease
Recruiting
The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease.
The purpose of this research study is to investigate how the brain, memory, thinking, and motor behavior change both in individuals with movement and/or cognitive disorders, as well as healthy individuals. Researchers will look at measurements of memory, thinking, brain wave and muscle activity, daily functioning, and brain scans to learn more about brain disorders such as Alzheimer disease and Lewy body disease. Read Less
Gender:
ALL
Ages:
Between 50 years and 95 years
Trial Updated:
01/27/2025
Locations: Mayo Clinic Arizona, Scottsdale, Arizona
Mayo Clinic Arizona, Scottsdale, Arizona
Conditions: Lewy Body Disease, Alzheimer Disease, Healthy
Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose
Recruiting
Background:
Researchers use mixed meal tolerance tests (MMTTs) to look at how people s bodies respond to eating a meal. However, researchers do not agree on how to decide the number of calories to give in each meal. Some use fixed meals, which are the same size for everyone, and some use adjusted meals, based on the size of the person s body. Researchers want to know which MMTT is best to use for future research.
Objective:
To learn how fixed vs adjusted meals affect blood glucose levels in h... Read More
Background:
Researchers use mixed meal tolerance tests (MMTTs) to look at how people s bodies respond to eating a meal. However, researchers do not agree on how to decide the number of calories to give in each meal. Some use fixed meals, which are the same size for everyone, and some use adjusted meals, based on the size of the person s body. Researchers want to know which MMTT is best to use for future research.
Objective:
To learn how fixed vs adjusted meals affect blood glucose levels in healthy people.
Eligibility:
Healthy people aged 18 years or older.
Design:
Participants will have 3 or 4 clinic visits of up to 8 hours in 8 weeks.
Participants will have baseline tests:
Their height, weight, and waist size will be measured.
They will have an oral glucose tolerance test: A needle attached to a tube (IV) will be inserted into a vein in the arm. They will have a sugary drink. Blood samples will be taken from the tube at intervals up to 3 hours after the drink.
They will have a body scan.
Participants will have 2 MMTT visits. One will include a fixed meal and one will include an adjusted meal. They will have tests at both visits:
Resting metabolic rate: A clear hood will be placed over the participant s head while they rest for 20 minutes. This will measure the oxygen they breathe in and out.
MMTT. Participants will have 5 minutes to drink a liquid meal. Blood samples will be taken at intervals for the next 4 hours.... Read Less
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
07/11/2025
Locations: NIDDK, Phoenix, Phoenix, Arizona
NIDDK, Phoenix, Phoenix, Arizona
Conditions: Obesity, Healthy Volunteer
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
Recruiting
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function. Read Less
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/01/2024
Locations: Arizona Liver Health, Chandler, Arizona +1 locations
Arizona Liver Health, Chandler, Arizona
Local Institution - 0004, Chandler, Arizona
Conditions: Hepatic Impairment, Healthy Volunteers
A Phase I Study of CDX-622
Recruiting
This is a study to determine the safety of CDX-622 in healthy participants.
This is a study to determine the safety of CDX-622 in healthy participants. Read Less
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/15/2025
Locations: Celerion, Inc., Tempe, Arizona
Celerion, Inc., Tempe, Arizona
Conditions: Healthy Participants
Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA
Recruiting
The purpose of this research is to collect medical imaging data to allow for the comparison of bone mineral density measurements from two different types of low-dose x-ray exams, EOSedge and conventional DXA. The main question it aims to answer is:
Is there agreement between the calculated T-scores between the 2 different types of x-ray exams?
The purpose of this research is to collect medical imaging data to allow for the comparison of bone mineral density measurements from two different types of low-dose x-ray exams, EOSedge and conventional DXA. The main question it aims to answer is:
Is there agreement between the calculated T-scores between the 2 different types of x-ray exams? Read Less
Gender:
ALL
Ages:
20 years and above
Trial Updated:
02/12/2025
Locations: Honor Health, Phoenix, Arizona
Honor Health, Phoenix, Arizona
Conditions: Healthy, Indicated for EOSedge Imaging
Increasing Physical Activity Through Social Support and Stress Resilience
Recruiting
The goal of this clinical trial is to learn the effects of technology enhancements when combined with basic education, goal-setting, and self-monitoring to increase physical activity among older adults living alone, experiencing subjective cognitive decline, and currently engaging minimal physical activity (60 minutes or less of moderate to vigorous physical activity). Further, we will examine key psychosocial mechanisms believed to contribute to successful promotion of physical activity, which... Read More
The goal of this clinical trial is to learn the effects of technology enhancements when combined with basic education, goal-setting, and self-monitoring to increase physical activity among older adults living alone, experiencing subjective cognitive decline, and currently engaging minimal physical activity (60 minutes or less of moderate to vigorous physical activity). Further, we will examine key psychosocial mechanisms believed to contribute to successful promotion of physical activity, which include social support and stress resilience.
The primary questions are to determine whether
* the tech-enhanced condition lead to greater physical activity over time?
* the tech-enhanced condition lead to social support and stress resilience over time?
* social support and stress resilience mediate the relationship between the study condition and physical activity?
All participants will engage in self-monitoring of physical activity, will receive weekly text reminders of their physical activity goals for the week, and will receive basic education about the importance of physical activity, social support, and stress resilience for cognitive, physical, and psychological health. Participants in the tech-enhanced condition will also receive access to a study-specific website and virtual coaching to reinforce the information presented. Researchers will then compare the tech-enhanced condition to the basic education condition to determine the benefits of technology to deliver the intervention materials in order to increase physical activity, social support, and stress resilience.
Participants will:
* Use a Garmin wearable device to monitor their physical activity
* Be randomly assigned to a basic education condition or tech-enhanced condition
* Set achievable goals for weekly physical activity, with incremental increases to achieve 150 minutes per week by the end of the study
* Respond to surveys to monitor their social support, stress resilience, quality of life, and depression.
The sample has several risk factors for Alzheimer's disease and related dementias: low physical activity, social isolation risk via living alone, and subjective cognitive impairment. Therefore, a long-term goal includes the determination of the intervention's effectiveness at increasing physical activity, social support, and stress resilience to reduce risk for developing dementia. Read Less
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/22/2025
Locations: Arizona State University, Phoenix, Arizona
Arizona State University, Phoenix, Arizona
Conditions: Healthy, Subjective Cognitive Decline (SCD), Sedentary Behavior, Social Isolation in Older Adults
A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults
Recruiting
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules.
During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous \[SC\] infusion) on Day 1 at a lower dose level followed by participants receiving multiple infusion of higher dose levels.
Participants will be in the study for approximately 19 weeks including screening period and follow-up (End of Treatment \[EOT\]).
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules.
During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous \[SC\] infusion) on Day 1 at a lower dose level followed by participants receiving multiple infusion of higher dose levels.
Participants will be in the study for approximately 19 weeks including screening period and follow-up (End of Treatment \[EOT\]). Read Less
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/06/2025
Locations: Celerion, Tempe, Arizona
Celerion, Tempe, Arizona
Conditions: Healthy Volunteers
Medical Discoveries and Innovation in New Hampshire
New Hampshire is the 6th healthiest state in the United States. Over the years, the state has been a crucible of ingenuity, bringing countless medical achievements. Some of the most notable milestones are:
- Pioneered advancements in infant care: A multi-centered clinical trial from Dartmouth Hitchcock Clinic demonstrated an effective way to safely treat infants with Neonatal Opioid Withdrawal Syndrome (NOWS). The study showed that combining the Eat Sleep Console approach with the ESC Care Tool can be highly beneficial for babies who’ve been exposed to opioids while still in the womb.
- Cancer research: Norris Cotton Cancer Center is a beacon of hope for many cancer patients. Pioneering research in immunotherapy and precision medicine has led to improved outcomes and better survival rates.
- Vaccine Trials Network: New Hampshire’s network plays a crucial role in the development and testing of vaccines. Especially during critical moments, like the COVID-19 crisis, H1N1 pandemic, and HIV testing.
Why New Hampshire Is A Great Place For Clinical Research
New Hampshire clinical research can’t move forward without diverse data. The population here is relatively diverse. About 89.1% of its residents are White, 4.4% are Hispanic, 3% are Asian, 1.6% are Multiracial, and 1.5% are Black.